novo nordisk
- Europe
Novo Nordisk shares plunge on the back of disappointing trial results
Novo Nordisk shares have plunged 20% amid the disappointing trial result of its latest weight-loss drug CagriSema. The fall wiped…
Read More » - Europe
Eli Lilly shares rise as Zepbound weight-loss test shows solid success
Lilly said patients taking Zepbound lost about 20% of their weight on average compared with nearly 14% for Wegovy. The…
Read More » - Europe
Teens on anti-obesity drugs less likely to consider or attempt suicide
Researchers said the drugs don’t appear to raise the risk of suicidal thoughts or actions for young people but also…
Read More » - Europe
Novo Nordisk boss in US grilling over prices for weight-loss drugs
Novo Nordisk has been criticised by US politicians for the high pricing of its popular weight-loss and diabetes drugs. But…
Read More » - Europe
Weight loss market: Eli Lilly and Novo Nordisk’s rivals muscle in
As Eli Lilly and Novo Nordisk continue to dominate the lucrative weight-loss drug market, smaller competitors are gearing up to…
Read More »
